Comparison of oncologic outcomes between sarcomatoid and clear cell renal cell carcinoma

Vincent Trudeau, Alessandro Larcher, Maxine Sun, Katharina Boehm, Paolo Dell’Oglio, José Sosa, Zhe Tian, Nicola Fossati, Alberto Briganti, Shahrokh F. Shariat, Pierre I. Karakiewicz

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background: Sarcomatoid renal cell carcinoma (sRCC) is a rare histological subtype that is associated with unfavorable prognosis. We sought to examine the effect of sRCC on cancer-specific mortality (CSM) relative to clear cell renal cell carcinoma (ccRCC), after adjusting for other variables, as well as other-cause mortality (OCM). Methods: We relied on the Surveillance, Epidemiology, and End Results–Medicare database from 2000 to 2009 to identify a cohort of 7916 patients with either sRCC (n = 234) or ccRCC (n = 7682) who received surgery as primary treatment. Patient, tumor, and treatment characteristics were evaluated. Then, 5-year smoothed Poisson regression CSM and OCM estimates were generated for stage-by-stage comparisons between sRCC and ccRCC. A multivariable competing-risks regression model predicting CSM and adjusting for several patient and tumor characteristics, as well as OCM, was finally fitted. Results: Compared to ccRCC patients, sRCC patients had more advanced and more aggressive disease at diagnosis. Specifically, 48 and 7 % of sRCC and ccRCC patients presented with stage IV disease, respectively (p <0.001). Overall, 5-year CSM and OCM estimates were 67 and 17 % for sRCC patients and 14 and 19 % for ccRCC patients. In stage-by-stage analyses, sRCC was invariably associated with worse CSM. After adjusting for several characteristics as well as OCM, sRCC was associated with a 3.2 higher risk of CSM compared with ccRCC. Conclusions: Patients with sRCC are present with more advanced disease. Moreover, sRCC is associated with a higher rate of CSM, even after adjusting for several characteristics and OCM.

Original languageEnglish
Pages (from-to)1-8
Number of pages8
JournalWorld Journal of Urology
DOIs
Publication statusAccepted/In press - Feb 22 2016

Fingerprint

Renal Cell Carcinoma
Mortality
Neoplasms

Keywords

  • Cancer-specific mortality
  • Histological subtype
  • Kidney cancer
  • Oncological outcomes
  • Sarcomatoid

ASJC Scopus subject areas

  • Urology

Cite this

Trudeau, V., Larcher, A., Sun, M., Boehm, K., Dell’Oglio, P., Sosa, J., ... Karakiewicz, P. I. (Accepted/In press). Comparison of oncologic outcomes between sarcomatoid and clear cell renal cell carcinoma. World Journal of Urology, 1-8. https://doi.org/10.1007/s00345-016-1780-z

Comparison of oncologic outcomes between sarcomatoid and clear cell renal cell carcinoma. / Trudeau, Vincent; Larcher, Alessandro; Sun, Maxine; Boehm, Katharina; Dell’Oglio, Paolo; Sosa, José; Tian, Zhe; Fossati, Nicola; Briganti, Alberto; Shariat, Shahrokh F.; Karakiewicz, Pierre I.

In: World Journal of Urology, 22.02.2016, p. 1-8.

Research output: Contribution to journalArticle

Trudeau, V, Larcher, A, Sun, M, Boehm, K, Dell’Oglio, P, Sosa, J, Tian, Z, Fossati, N, Briganti, A, Shariat, SF & Karakiewicz, PI 2016, 'Comparison of oncologic outcomes between sarcomatoid and clear cell renal cell carcinoma', World Journal of Urology, pp. 1-8. https://doi.org/10.1007/s00345-016-1780-z
Trudeau, Vincent ; Larcher, Alessandro ; Sun, Maxine ; Boehm, Katharina ; Dell’Oglio, Paolo ; Sosa, José ; Tian, Zhe ; Fossati, Nicola ; Briganti, Alberto ; Shariat, Shahrokh F. ; Karakiewicz, Pierre I. / Comparison of oncologic outcomes between sarcomatoid and clear cell renal cell carcinoma. In: World Journal of Urology. 2016 ; pp. 1-8.
@article{d209b42537ec474ea775c8fb0814900b,
title = "Comparison of oncologic outcomes between sarcomatoid and clear cell renal cell carcinoma",
abstract = "Background: Sarcomatoid renal cell carcinoma (sRCC) is a rare histological subtype that is associated with unfavorable prognosis. We sought to examine the effect of sRCC on cancer-specific mortality (CSM) relative to clear cell renal cell carcinoma (ccRCC), after adjusting for other variables, as well as other-cause mortality (OCM). Methods: We relied on the Surveillance, Epidemiology, and End Results–Medicare database from 2000 to 2009 to identify a cohort of 7916 patients with either sRCC (n = 234) or ccRCC (n = 7682) who received surgery as primary treatment. Patient, tumor, and treatment characteristics were evaluated. Then, 5-year smoothed Poisson regression CSM and OCM estimates were generated for stage-by-stage comparisons between sRCC and ccRCC. A multivariable competing-risks regression model predicting CSM and adjusting for several patient and tumor characteristics, as well as OCM, was finally fitted. Results: Compared to ccRCC patients, sRCC patients had more advanced and more aggressive disease at diagnosis. Specifically, 48 and 7 {\%} of sRCC and ccRCC patients presented with stage IV disease, respectively (p <0.001). Overall, 5-year CSM and OCM estimates were 67 and 17 {\%} for sRCC patients and 14 and 19 {\%} for ccRCC patients. In stage-by-stage analyses, sRCC was invariably associated with worse CSM. After adjusting for several characteristics as well as OCM, sRCC was associated with a 3.2 higher risk of CSM compared with ccRCC. Conclusions: Patients with sRCC are present with more advanced disease. Moreover, sRCC is associated with a higher rate of CSM, even after adjusting for several characteristics and OCM.",
keywords = "Cancer-specific mortality, Histological subtype, Kidney cancer, Oncological outcomes, Sarcomatoid",
author = "Vincent Trudeau and Alessandro Larcher and Maxine Sun and Katharina Boehm and Paolo Dell’Oglio and Jos{\'e} Sosa and Zhe Tian and Nicola Fossati and Alberto Briganti and Shariat, {Shahrokh F.} and Karakiewicz, {Pierre I.}",
year = "2016",
month = "2",
day = "22",
doi = "10.1007/s00345-016-1780-z",
language = "English",
pages = "1--8",
journal = "World Journal of Urology",
issn = "0724-4983",
publisher = "Springer Verlag",

}

TY - JOUR

T1 - Comparison of oncologic outcomes between sarcomatoid and clear cell renal cell carcinoma

AU - Trudeau, Vincent

AU - Larcher, Alessandro

AU - Sun, Maxine

AU - Boehm, Katharina

AU - Dell’Oglio, Paolo

AU - Sosa, José

AU - Tian, Zhe

AU - Fossati, Nicola

AU - Briganti, Alberto

AU - Shariat, Shahrokh F.

AU - Karakiewicz, Pierre I.

PY - 2016/2/22

Y1 - 2016/2/22

N2 - Background: Sarcomatoid renal cell carcinoma (sRCC) is a rare histological subtype that is associated with unfavorable prognosis. We sought to examine the effect of sRCC on cancer-specific mortality (CSM) relative to clear cell renal cell carcinoma (ccRCC), after adjusting for other variables, as well as other-cause mortality (OCM). Methods: We relied on the Surveillance, Epidemiology, and End Results–Medicare database from 2000 to 2009 to identify a cohort of 7916 patients with either sRCC (n = 234) or ccRCC (n = 7682) who received surgery as primary treatment. Patient, tumor, and treatment characteristics were evaluated. Then, 5-year smoothed Poisson regression CSM and OCM estimates were generated for stage-by-stage comparisons between sRCC and ccRCC. A multivariable competing-risks regression model predicting CSM and adjusting for several patient and tumor characteristics, as well as OCM, was finally fitted. Results: Compared to ccRCC patients, sRCC patients had more advanced and more aggressive disease at diagnosis. Specifically, 48 and 7 % of sRCC and ccRCC patients presented with stage IV disease, respectively (p <0.001). Overall, 5-year CSM and OCM estimates were 67 and 17 % for sRCC patients and 14 and 19 % for ccRCC patients. In stage-by-stage analyses, sRCC was invariably associated with worse CSM. After adjusting for several characteristics as well as OCM, sRCC was associated with a 3.2 higher risk of CSM compared with ccRCC. Conclusions: Patients with sRCC are present with more advanced disease. Moreover, sRCC is associated with a higher rate of CSM, even after adjusting for several characteristics and OCM.

AB - Background: Sarcomatoid renal cell carcinoma (sRCC) is a rare histological subtype that is associated with unfavorable prognosis. We sought to examine the effect of sRCC on cancer-specific mortality (CSM) relative to clear cell renal cell carcinoma (ccRCC), after adjusting for other variables, as well as other-cause mortality (OCM). Methods: We relied on the Surveillance, Epidemiology, and End Results–Medicare database from 2000 to 2009 to identify a cohort of 7916 patients with either sRCC (n = 234) or ccRCC (n = 7682) who received surgery as primary treatment. Patient, tumor, and treatment characteristics were evaluated. Then, 5-year smoothed Poisson regression CSM and OCM estimates were generated for stage-by-stage comparisons between sRCC and ccRCC. A multivariable competing-risks regression model predicting CSM and adjusting for several patient and tumor characteristics, as well as OCM, was finally fitted. Results: Compared to ccRCC patients, sRCC patients had more advanced and more aggressive disease at diagnosis. Specifically, 48 and 7 % of sRCC and ccRCC patients presented with stage IV disease, respectively (p <0.001). Overall, 5-year CSM and OCM estimates were 67 and 17 % for sRCC patients and 14 and 19 % for ccRCC patients. In stage-by-stage analyses, sRCC was invariably associated with worse CSM. After adjusting for several characteristics as well as OCM, sRCC was associated with a 3.2 higher risk of CSM compared with ccRCC. Conclusions: Patients with sRCC are present with more advanced disease. Moreover, sRCC is associated with a higher rate of CSM, even after adjusting for several characteristics and OCM.

KW - Cancer-specific mortality

KW - Histological subtype

KW - Kidney cancer

KW - Oncological outcomes

KW - Sarcomatoid

UR - http://www.scopus.com/inward/record.url?scp=84959127397&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959127397&partnerID=8YFLogxK

U2 - 10.1007/s00345-016-1780-z

DO - 10.1007/s00345-016-1780-z

M3 - Article

SP - 1

EP - 8

JO - World Journal of Urology

JF - World Journal of Urology

SN - 0724-4983

ER -